Clinical Trial Update: Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TRO40303 for reducing reperfusion injury in patients undergoing PCI for acute myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• TRO40303

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Acute Myocardial Infarctus | Phase 2 | Status: COMPLETED